
Last updated: 2026-10-14 16:00:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
First Tracks Biotherapeutics, Inc. (TRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33.10, with a market capitalisation of $1.22B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $49.91. This page covers its latest market performance, valuation, price trends and company information.
$1.22B | |
$31.28 | |
$49.91 | |
$14.72 | |
$31.68 | |
226.90K | |
828.54K | |
-- | |
$49.91 | |
$14.72 | |
-- | |
-- |
First Tracks Biotherapeutics, Inc. (TRAX) is currently trading at $33.10 as of 2026-10-14 15:44:28, up 4.49% ($1.42) from the previous close of $31.68
During today's regular trading session, TRAX has traded between $14.72 and $49.91, with a trading volume of 226.90K shares. The current price is near the middle of today's range.
Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAX) moved from $32.99 to $33.10, representing a gain of 0.35% ($0.11).
The stock traded between $30.11 and $40.50 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 1.77 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 52.2%
TRAX is currently trading at $33.10, placing it 52.2% of the way from its 52-week low of $14.72 to its 52-week high of $49.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.